Financing - September 18, 2014
Pulmologix raises EUR 9.6 million
Swedish Pulmologix AB has closed a series B financing of EUR 9.6 million to develop a new oral non-steroidal anti-asthmatic (ONSA) for the treatment of early onset allergic asthma. According to a press release, the financing was led by Novo Seeds, the seed fund of Novo A/S, and Sunstone Capital of Denmark. Previous investors Forbion Capital Partners […]
Uncategorized - September 17, 2014
New agreement tightens up requirements
On September 11, the Swedish government and the Swedish Association of Local Authorities and Regions signed a new agreement regarding the regulation of the funding allocated to clinical research. ALF, which stands for an agreement between the Swedish state and some county councils on collaboration regarding basic training of physicians, medical research and the development of […]
Agreement - September 17, 2014
AstraZeneca and Eli Lilly enter agreement
The two companies have announced an alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease. The aim is to progress AZD3293 rapidly into a Phase II/III clinical trial in patients with early Alzheimer’s disease. Lilly will lead clinical development, working with researchers from AstraZeneca’s Innovative Medicines Unit for neuroscience, while AstraZeneca will be responsible […]
Financing - September 16, 2014
New owner for Diamyd Medical
Diamyd Medical is extending its collaboration with Protein Sciences regarding the development of diabetes treatment. Following the new agreement the American firm becomes one of the larger share holders of Diamyd. Diamyd Medical and Protein Sciences Corporation have announced that Protein Sciences has broadened its commitment to diabetes and become a strategic and significant shareholder […]
Clinical Trials - September 16, 2014
Ascendis Pharma A/S announces positive results from phase II study
The Danish biotechnology company Ascendis Pharma A/S has announced positive interim results from its ongoing Phase 2 pediatric study. The study regards evaluating once-weekly TransCon Growth Hormone in children with growth hormone deficiency, or GHD. “It has been demonstrated that patients who do not comply with the daily injection regimen of currently available growth hormone therapies suffer from […]
Agreement - September 16, 2014
BioLamina enters agreement with Corning
Corning Incorporated has entered into an agreement with BioLamina to manufacture and package the Recombinant Laminin-521 (rLaminin-521) pluripotent stem-cell and neural stem-cell growth matrix. “As cell-culture and cell-therapy technologies progress, it is increasingly important to offer today’s researchers more powerful and reliable culture systems,” said Kristian Tryggvason, Ph.D., CEO, BioLamina. “Through this agreement with Corning, […]
